LncRNA in tumorigenesis of non-small-cell lung cancer: From bench to bedside

Hu, Qin; Ma, Huiyun; Chen, Hongyu; Zhang, Zhouwei; Xue, Qun

doi:10.1038/s41420-022-01157-4

Cited by 36 publications

(26 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies demonstrated that some transcripts that are annotated as lncRNAs actually encode for small proteins and that lncRNAs can be processed into small ncRNAs such as miRNAs or piRNAs [ 198 , 199 , 200 ]. LncRNAs can exert oncogenic or tumor suppressor functions affecting different biological processes such as cell proliferation, cell death and drug resistance [ 201 , 202 , 203 ]. LncRNAs can be secreted into the circulation system via exosomes or bound to RBPs.…”

Section: Non-coding Rnasmentioning

confidence: 99%

Non-Coding RNAs Modulating Estrogen Signaling and Response to Endocrine Therapy in Breast Cancer

Treeck¹,

Ortmann²

2023

Cancers

View full text Add to dashboard Cite

The largest part of human DNA is transcribed into RNA that does not code for proteins. These non-coding RNAs (ncRNAs) are key regulators of protein-coding gene expression and have been shown to play important roles in health, disease and therapy response. Today, endocrine therapy of ERα-positive breast cancer (BC) is a successful treatment approach, but resistance to this therapy is a major clinical problem. Therefore, a deeper understanding of resistance mechanisms is important to overcome this resistance. An increasing amount of evidence demonstrate that ncRNAs affect the response to endocrine therapy. Thus, ncRNAs are considered versatile biomarkers to predict or monitor therapy response. In this review article, we intend to give a summary and update on the effects of microRNAs (miRNAs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) on estrogen signaling in BC cells, this pathway being the target of endocrine therapy, and their role in therapy resistance. For this purpose, we reviewed articles on these topics listed in the PubMed database. Finally, we provide an assessment regarding the clinical use of these ncRNA types, particularly their circulating forms, as predictive BC biomarkers and their potential role as therapy targets to overcome endocrine resistance.

show abstract

Section: Non-coding Rnasmentioning

confidence: 99%

Non-Coding RNAs Modulating Estrogen Signaling and Response to Endocrine Therapy in Breast Cancer

Treeck¹,

Ortmann²

2023

Cancers

View full text Add to dashboard Cite

show abstract

“…LncRNA is non-coding RNA with a length >200 bp, which is a major regulator of gene expression [212]. LncRNA can interact with miRNA and affect the proliferation, invasion and metastasis of NSCLC cells [218]. LncRNA XLOC_008466 is highly expressed in patients with NSCLC and binds to miR-874 to down-regulate its level and increase miR-874 downstream target expression to promote cancer cell proliferation and invasion [219].…”

Section: Non-coding Rnamentioning

confidence: 99%

Advances in Targeted Therapy Against Driver Mutations and Epigenetic Alterations in Non-Small Cell Lung Cancer

Shi¹,

Chen²,

Peng³

et al. 2022

Oncologie

View full text Add to dashboard Cite

The incidence and mortality of lung cancer rank top three of all cancers worldwide. Accounting for 85% of the total number of lung cancer, non-small cell lung cancer (NSCLC) is an important factor endangering human health. Recently, targeted therapies against driver mutations and epigenetic alterations have made encouraging advances that benefit NSCLC patients. Druggable driver mutations, which mainly occur in EGFR, KRAS, MET, HER2, ALK, ROS1, RET and BRAF, have been identified in more than a quarter of NSCLC patients. A series of highly selective mutant targeting inhibitors, such as EGFR tyrosine kinase inhibitors and KRAS inhibitors, have been well studied and applied in clinical treatments, which greatly promote the overall survival of NSCLC patients. However, drug resistance has become a major challenge for targeted treatment, and a variety of methods to overcome drug resistance are constantly being developed, including inhibitors against new mutants, combination therapy with other pathway inhibitors, etc. In addition, epigenetics-based therapy is emerging. Epigenetic regulators such as histone deacetylases and non-coding RNA play a crucial role in the development of cancer and drug resistance by affecting multiple signaling pathways. Epigenetics-based therapeutic strategies combined with targeted drugs show great clinical potential. Many agents targeting epigenetic changes are being investigated in preclinical studies, with some already under clinical trials. This article focuses on driver mutations and epigenetic alterations in association with relevant epidemiological data. We introduce the current status of targeted inhibitors and known drug resistance, review advances in major targeted therapies with recent data from preclinical and clinical trials, and discuss the possibility of combination therapy against driver mutations and epigenetic alterations in overcoming drug resistance.

show abstract

“…Non-coding RNAs have been reported to involved in human cancer development and progression ( Ghafouri-Fard et al, 2020 ; Yan and Bu, 2021 ; Chen T. et al, 2022 ; Liu and Shang, 2022 ). Evidence has shown that lncRNAs play an essential role in NSCLC initiation, development and progression ( Osielska and Jagodzinski, 2018 ; Wang et al, 2018 ; Hu et al, 2022 ). Moreover, non-coding RNAs are critically involved in cancer drug resistance in human cancers ( Jiang et al, 2020 ; Zhou X. et al, 2022 ; Xie et al, 2022 ).…”

Section: Introductionmentioning

confidence: 99%

Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer

Wang

Zhu²,

Yang³

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Lung cancer is the common malignant tumor with the highest mortality rate. Lung cancer patients have achieved benefits from immunotherapy, including immune checkpoint inhibitors (ICIs) therapy. Unfortunately, cancer patients acquire adaptive immune resistance, leading to poor prognosis. Tumor microenvironment (TME) has been demonstrated to play a critical role in participating in acquired adaptive immune resistance. TME is associated with molecular heterogeneity of immunotherapy efficacy in lung cancer. In this article, we discuss how immune cell types of TME are correlated with immunotherapy in lung cancer. Moreover, we describe the efficacy of immunotherapy in driven gene mutations in lung cancer, including KRAS, TP53, EGFR, ALK, ROS1, KEAP1, ZFHX3, PTCH1, PAK7, UBE3A, TNF-α, NOTCH, LRP1B, FBXW7, and STK11. We also emphasize that modulation of immune cell types of TME could be a promising strategy for improving adaptive immune resistance in lung cancer.

show abstract

LncRNA in tumorigenesis of non-small-cell lung cancer: From bench to bedside

Cited by 36 publications

References 64 publications

Non-Coding RNAs Modulating Estrogen Signaling and Response to Endocrine Therapy in Breast Cancer

Non-Coding RNAs Modulating Estrogen Signaling and Response to Endocrine Therapy in Breast Cancer

Advances in Targeted Therapy Against Driver Mutations and Epigenetic Alterations in Non-Small Cell Lung Cancer

Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer

Contact Info

Product

Resources

About